KumarS.K.TherneauT.M.GertzM.A.Clinical course of patients with relapsed multiple myelomaMayo Clin Proc2004; 79:867–874.
2.
Canadian Cancer Society's Steering CommitteeCanadian Cancer Statistics 2010. Public Health Agency of Canada2010Canadian Cancer SocietyToronto
3.
AlexanderD.D.MinkP.J.AdamiH.O.Multiple myeloma: a review of the epidemiologic literatureInt J Cancer2007; 120:40–61.
4.
MadanS.KumarS.Review extramedullary disease in multiple myelomaClin Adv Hematol Oncol2009; 7:802–804.
5.
ZappasodiP.CorsoA.KlersyC.Changes in multiple myeloma epidemiology in the last thirty years: a single centre experienceEur J Cancer2006; 42:396–402.
6.
KatodritouE.GastariV.VerrouE.Extramedullary (EMP) relapse in unusual locations in multiple myeloma: is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?Leuk Res2009; 33:1164–1165.
7.
CandoniA.SimeoneE.FaninR.Extramedullary progression of multiple myeloma under thalidomide therapy despite concomitant response of medullary diseaseAm J Hematol2008; 83:680–681.
